Semaglutide for prediabetic state

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 15 Nov 2021: Trial registered, NCT05119179
  2. 22 Nov 2021: Trial started, NCT05119179
  3. 27 Mar 2023: Trial registered, NCT05786521
  4. 1 Apr 2023: Trial started, NCT05786521

The trials

NCT05067621: Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

State
Under way
Phase
Phase 2
People
60 taking part
Started
17 Jul 2023
Primary completion
Dec 2026
Arms
Receive treatment
Results
None posted
  1. 5 Oct 2021: Trial registered
  2. 17 Jul 2023: Trial started

NCT05119179: Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

State
Under way
Phase
Phase 4
People
300 planned
Started
22 Nov 2021
Primary completion
31 Oct 2026
Arms
Semaglutide
Results
None posted
  1. 15 Nov 2021: Trial registered
  2. 22 Nov 2021: Trial started

NCT05786521: Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

State
Completed
Phase
Phase 4
People
20 taking part
Started
1 Apr 2023
Primary completion
20 May 2024
Arms
Semaglutide and lifestyle intervention
Results
Posted on the registry
  1. 27 Mar 2023: Trial registered
  2. 1 Apr 2023: Trial started
  3. 20 May 2024: Trial completed
  4. 4 May 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.